Clinical Trials Logo

Citation(s)

A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers

Details for clinical trial NCT00781846